[医药卫生]朱广迎 局部晚期非小细胞肺癌同步放化疗规范及ASTRO进展.pdfVIP

2011肺癌放射治疗新进展 ———2011美国ASTRO会议报告 北京大学肿瘤医院 朱广迎 2011 ASTRO会议肺癌参会文章  1.大会发言：共23篇（中国1篇）  2.壁报讨论：共12篇（中国1篇） 3.壁报：共116篇（中国12篇） 2011 ASTRO会议报告  1.提高剂量的多中心随机研究  2.以放射治疗为主的综合治疗 3.FDG—PET在肺癌放射治疗中的应用 4.放射性损伤的研究进展 RTOG 0617 A Randomized Phase III Comparison Of Standard-Dose (60 Gy) Versus High-Dose (74 Gy) Conformal Radiotherapy With Concurrent And Consolidation Carboplatin/Paclitaxel +/- Cetuximab In Patients With Stage IIIA/IIIB Non- Small Cell Lung Cancer Intergroup Paticipation : RTOG, NCCTG, CALGB Schema *Carboplatin and paclitaxel Primary objective  To compare the overall survival of patients treated with high-dose versus standard-dose conformal radiation therapy in the setting of concurrent chemotherapy.  To compare the overall survival of patients treated with cetuximab versus without cetuximab with concurrent chemotherapy . Eligibility Criteria  Newly diagnosed, unresectable Stage IIIA/B NSCLC; patients who present with N2/N3 disease and an undetectable NSCLC primary tumor are also eligible  No suptaclavicular or contralateral hilar adenopathy  Zubrod 0/1  Age ≥18  FEV1 ≥1.2 liters/second or ≥50% predicted  ANC ≥1,000, platelets≥100,000, Hgb ≥10.0 g/dl  Serum vreatinine within normal institutional limits, or creatinine clearance 60 ml/min, bilirubin within naomal institutional limits; AST and ALT 2.5 X IULN  Signed informed consent RTOG 0617 Date opened November 2007 Targeted accrual 500 Projected monthly accrual 9 Average monthly accrual